Lewis T. Williams net worth and biography

Lewis Williams Biography and Net Worth

Dr. Williams has served on our board of directors since June 2017 and is chair of the Research Committee and a member of the Compensation Committee. He is also Chairman of the Boards of Realta Therapeutics and Ten30 Biosciences. Dr. Williams founded and served as a CEO, Director, and Chairman of Five Prime Therapeutics, Inc., a former public biotechnology company acquired by Amgen, Inc in 2021. He was also Co-Founder and Board member of Cor Therapeutics which was acquired by Millenium Pharmaceuticals. In 2019 he was a co-founder and CEO of Walking Fish Therapeutics, a cell therapy company. Previously, Dr. Williams spent seven years at Chiron Corporation, a biopharmaceutical company now known as Novartis Vaccines and Diagnostics, Inc., where he served as its Chief Scientific Officer and a member of the Board of Directors. Prior to joining Chiron, Dr. Williams was a professor of medicine at the University of California, San Francisco, and was an Investigator of the Howard Hughes Medical Institute. Dr. Williams also has served on the faculties of Harvard Medical School and Massachusetts General Hospital. He is a member of the National Academy of Sciences and a fellow of the American Academy of Arts and Sciences. He is currently on the Boards of the Institute for Protein Innovation and the Woodshole Marine Biological Laboratories, and has previously served on the Boards of Trustees of Duke University, Rice University, and The Berklee College of Music. Dr. Williams received a B.S. from Rice University and an M.D. and a Ph.D. from Duke University.

What is Lewis T. Williams' net worth?: The estimated net worth of Lewis T. Williams is at least $692.16 thousand as of February 17th, 2026. Williams owns 7,825 shares of Protagonist Therapeutics stock worth more than $692,160 as of February 26th. This net worth approximation does not reflect any other assets that Williams may own. Learn More about Lewis T. Williams' net worth.
How do I contact Lewis T. Williams?: The corporate mailing address for Williams and other Protagonist Therapeutics executives is 7707 GATEWAY BOULEVARD SUITE 140, NEWARK CA, 94560. Protagonist Therapeutics can also be reached via phone at (510) 474-0170 and via email at [email protected]. Learn More on Lewis T. Williams' contact information.
Has Lewis T. Williams been buying or selling shares of Protagonist Therapeutics?: During the last quarter, Lewis T. Williams has sold $1,483,560.00 in Protagonist Therapeutics stock. Most recently, Lewis T. Williams sold 18,000 shares of the business's stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $82.42, for a transaction totalling $1,483,560.00. Following the completion of the sale, the director now directly owns 7,825 shares of the company's stock, valued at $644,936.50. Learn More on Lewis T. Williams' trading history.
Who are Protagonist Therapeutics' active insiders?: Protagonist Therapeutics' insider roster includes Asif Ali (EVP, CFO), Suneel Gupta (Chief Development Officer), David Liu (Insider), Arturo Molina (Chief Medical Officer), Dinsesh Patel (CEO), William Waddill (Director), and Lewis Williams (Director). Learn More on Protagonist Therapeutics' active insiders.
Are insiders buying or selling shares of Protagonist Therapeutics?: In the last year, insiders at the sold shares 23 times. They sold a total of 357,199 shares worth more than $25,844,696.52. The most recent insider tranaction occured on February, 17th when Director Lewis T Williams sold 18,000 shares worth more than $1,483,560.00. Insiders at Protagonist Therapeutics own 4.9% of the company. Learn More about insider trades at Protagonist Therapeutics.
Information on this page was last updated on 2/17/2026.

Lewis T. Williams Insider Trading History at Protagonist Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/17/2026	Sell	18,000	$82.42	$1,483,560.00	7,825

Lewis T. Williams Buying and Selling Activity at Protagonist Therapeutics

Protagonist Therapeutics Company Overview

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Today's Range

Now: $88.39

$85.60

$88.83

50 Day Range

MA: $84.07

$79.73

$88.78

2 Week Range

Now: $88.39

$35.95

$96.54

Volume

706,008 shs

Average Volume

735,214 shs

Market Capitalization

$5.53 billion

P/E Ratio

142.57

Dividend Yield

N/A

Beta

2.26